Comment from Pharmaceutical Research and Manufacturers of America (PhRMA)

Summary: PhRMA, representing the pharmaceutical research and manufacturing industry, supports the FDA's proposed pilot program to explore AI-enabled optimization in early-phase clinical trials. They advocate for a risk-based approach to AI validation, the protection of confidential commercial information, and the use of established practices to share learnings from the pilot.